A review of first-in-human small molecule oncology clinical trials
DOI:
https://doi.org/10.18203/2349-3259.ijct20162790Keywords:
First-in-human, Oncology, Cancer, Clinical trials, Small moleculeAbstract
First-in-human (FIH) oncology clinical trials are crucial to the development of small-molecule oncology candidates. However, there is a dearth of research investigating how these trials vary from one-another and therefore whether one approach may be better than another. This review aims to investigate variation of FIH trials published over the last decade with respect to four areas: publication particulars; trial design; patient particulars and drug administration and formulation.
References
International Agency for Research on Cancer. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 10 April 2015.
World Health Organization. Cancer Fact Sheet. Available from: http://www.who.int/mediacentre/ factsheets/fs297/en/. Accessed 16 February 2016.
Hirsch B, Califf M, Cheng S, Tasneem A, Horton J, Chiswell K, et al. Characteristics of oncology clinical trials: Insights from a systematic analysis of clinicaltrials.gov. JAMA Intern Med. 2013;173(11):972-9.
Tourneau C, Lee J, Siu L. Dose Escalation Methods in Phase I Cancer Clinical Trials. JNCI Journal of the National Cancer Institute. J Natl Cancer Inst. 2009;101(10):708-20.
World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available from: http://www.wma.net/en/30publications/10policies/b3/. Accessed 16 February 2016.
IMS Institute for Healthcare Informatics. Innovation in cancer care and implications for health systems. Availablefrom:http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-oncology-trend-report-2014#ims-form. Accessed 10 May 2015.
Kummar S, Gutierrez M, Anderson L, Klecker R, Chen A, Murgo A, et al. Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas. Cancer Chemoth Pharm. 2013;72(4):917-23.
Rodon J, Carducci M, Sepulveda-Sanchez J, Azaro A, Calvo E, Seoane J, et al. First-in-Human Dose Study of the Novel Transforming Growth Factor- Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clin Cancer Res. 2015;21(3):553-60.
Shapiro G, Kwak E, Dezube B, Yule M, Ayrton J, Lyons J, et al. First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015;21(1):87-97.
Sarker B, Ang J, Baird R, Kristeleit R, Shah K, Moreno V et al. First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86.
Hong D, Henary H, Falchook G, Naing A, Fu S, Moulder S, et al. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-B and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014;32(6):1204-12.
Blagden S, Olmin A, Josephs D, Stavraka C, Zivi A, Pinato D, et al. First-in-Human study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics and Pharmacodynamics, in Patients with Metastatic Cancer. Clin Cancer Res. 2014;20(23):5908-17.
Shimizu T, LoRusso P, Papadopoulos K, Patnaik A, Beeram M, Smith L, et al. Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014;20(19):5032-40.
Isambert N, Delord J, Soria J, Hollebecque A, Gomez-Roca C, Purcea D, et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer - results of a first-in-man dose escalation study with a fixed dose extension phase. Ann Oncol. 2015;26(5):1005-11.
Elez M, Tabernero J, Geary D, Macarulla T, Kang S, Kahatt C, et al. First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014;20(8):2205-14.
Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, et al. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemoth Pharm. 2014;73(3):577-83.
Pant S, Burris H, Moore K, Bendell J, Kurkjian C, Jones S, et al. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014;32(1):87-93.
Nemunaitis J, Small K, Kirschmeier P, Zhang D, Zhu Y, Jou Y, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med. 2013;11:259.
Brunetto A, Ang J, Lal R, Olmos D, Molife L, Kristeleit R, et al. First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Research. 2013;19(19):5494-504.
Ossenkoppele G, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht A, et al. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Brit J Haematol. 2013;162(2):191-201.
Sessa C, Shapiro G, Bhalla K, Britten C, Jacks K, Mita M, et al. First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2013;19(13):3671-80.
Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, et al. First-in-Human Phase 0 Trial of Oral 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) in Patients with Advanced Malignancies. Clin Cancer Research. 2013;19(7):1852-7.
Goldman J, Raju R, Gordon G, El-Hariry I, Teofilivici F, Vukovic V, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152.
Yap T, Arkenau H, Camidge D, George S, Serkova N, Gwyther S, et al. First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies. Clin Cancer Res. 2013;19(4):909-19.
Tibes R, Fine G, Choy G, Redkar S, Taverna P, Oganesian A, et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemoth Pharm. 2012;71(2):463-71.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer. 2013;49(2):290-6.
Lehmann S, Bykov V, Ali D, Andren O, Cherif H, Tidefelt U, et al. Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. J Clin Oncol. 2012;30(29):3633-9.
Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodere F, et al. First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clin Cancer Res. 2012;18(17):4806-19.
Hong D, Kurzrock R, Supko J, He X, Naing A, Wheler J, et al. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2012;18(12):3396-406.
'Yap T, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, et al. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br J Cancer. 2012;106(8):1379-85.
Chung V, Heath E, Schelman W, Johnson B, Kirby L, Lynch K, et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemoth and Pharm. 2011;69(3):733-41.
Doi T, Takiuchi H, Ohtsu A, Fuse N, Goto M, Yoshida M, et al. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer. 2012;106(4):666-72.
Yap T, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. J Clin Onc. 2011;29(35):4688-95.
Tabernero J, Dirix L, Schoffski P, Cervantes A, Lopez-Martin J, Capdevila J, et al. Clin Cancer Res. 2011;17(19):6313-21.
Massard C, Soria J, Anthoney D, Proctor A, Scaburri A, Pacciarini M, et al. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011;10(6):963-70.
Holen K, Belani C, Wilding G, Ramalingam S, Volkman J, Ramanathan R, et al. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemoth Pharm. 2011;67(2):447-54.
Mita M, Spear M, Yee L, Mita A, Heath E, Papadopoulos K, et al. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas. Clin Cancer Res. 2010;16(23):5892-9.
Kolesar J, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, et al. A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prev Res. 2010;3(12):1565-70.
Unger C, Berdel W, Hanauske A, Sindermann H, Engel J, Mross K. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer. 2010;46(5):920-5.
Goss G, Siu L, Gauthier I, Chen E, A Oza, R Goel, et al. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemoth Pharm. 2006;58(5):703-10.
Tsimberidou A, Rudek M, Hong D, Ng C, Blair J, Goldsweig H, et al. Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemoth Pharm. 2009;65(2):235-41.
Reid A, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, et al. A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2009;15(15):4978-85.
Dudek A, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, et al. First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer. Clin Cancer Res. 2007;13(23):7119-25.
Camidge D, Smethurst D, Growcott J, Barrass N, Foster J, Febbraro S, et al. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemoth Pharm. 2006;60(3):391-8.
Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014;105(3):347-53.
Hurwitz H, Smith D, Pitot H, Brill J, Chugh R, Rouits E, et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemoth Pharm. 2015;75(4):851-9.
LoRusso P, Goncalves P, Casetta L, Carter J, Litwiler K, Roseberry D, et al. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(2):440-9.
Schoffski P, Jones S, Dumez H, Infante J, Van Mieghem E, Fowst C, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer. 2011;47(15):2256-64.
Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol. 2010;21(3):633-9.
Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, et al. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Invest New Drugs. 2013;31(6):1530-8.
Lam E, Goel S, Schaaf L, Cropp G, Hannah A, Zhou Y, et al. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemoth Pharm. 2012;69(2):523-31.
Infante J, Dees E, Olszanski A, Dhuria S, Sen S, Cameron S, et al. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014;32(28):3103-10.
Infante J, Weiss G, Jones S, Tibes R, Bauer T, Bendell J, et al. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 2014;50(17):2897-904.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975-85.
Bendell J, Hong D, Burris H, Naing A, Jones S, Falchook G, et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemoth Pharm. 2014;74(1):125-30.
Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, et al. Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2011;17(8):2528-37.
Ghamande S, Lin C, Cho D, Shapiro G, Kwak E, Silverman M, et al. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2013;32(3):445-51.
Saif M, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, et al. A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014;20(2):445-55.
Patnaik A, Papadopoulos K, Tolcher A, Beeram M, Urien S, Schaaf L, et al. Phase I Dose-Escalation Study of EZN-2208 (PEG-SN38), a Novel Conjugate of Poly(ethylene) Glycol and SN38, Administered Weekly in Patients With Advanced Cancer. Cancer Chemoth Pharm. 2013;71(6):1499-506.
Eder J, Shapiro G, Appleman L, Zhu A, Miles D, Keer H, et al. A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2. Clin Cancer Res. 2010;16(13):3507-16.
Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, et al. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. Clin Cancer Res. 2009;15(23):7368-74.
Infante J, Camidge D, Mileshkin L, Chen E, Hicks R, Rischin D, et al. Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. J Clin Oncol. 2012;30(13):1527-33.
Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, et al. A Phase I Dose-scalation Study of Regorafenib (BAY 73GÇô4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2012;18(9):2658-67.
Wong K, Fracasso P, Bukowski R, Lynch T, Munster P, Shapiro G, et al. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. Clin Cancer Res. 2009;5(7):2552-8.
Rosen L, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage R, et al. A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors. Clin Cancer Res. 2011;17(24):7754-64.
Schwartz G, LoRusso P, Dickson M, Randolph S, Shaik M, Wilner K, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862-8.
Spicer J, Baird R, Suder A, Cresti N, Corbacho J, Hogarth L, et al. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Eur J Cancer. 2015;51(2):137-45.
Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer. 2012;48(2):179-86.
Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, et al. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer. 2010;46(4):729-34.
Scott E, Thomas A, Molife L, Ahmed S, Blagden S, Fong P, et al. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours. Cancer Chemoth Pharm. 2009;64(2):425-9.
Kitzen J, de Jonge M, Lamers C, Eskens F, van der Biessen D, van Doorn L, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer. 2009;45(10):1764-72.
Strumberg D, Schultheis B, Adamietz I, Christensen O, Buechert M, Kraetzschmar J, et al. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer. 2008;99(10):1579-85.
Eskens F, Mom C, Planting A, Gietema J, Amelsberg A, Huisman H, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80-5.
Corcoran M, Hovens C, Michael M, Rosenthal M, Costello A. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 2010;103(4):462-8.
Rodon J, Tawbi H, Thomas A, Stoller R, Turtschi C, Baselga J, et al. A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014;20(7):1900-9.
Cancer Research UK. Worldwide cancer
incidence statistics, 2014. Available from: http://www.cancerresearchuk.org/health-professi-onal/cancer-statistics/worldwide-cancer/incidence #heading-Zero. Accessed 20 April 2015.
Cancer Research UK. Worldwide cancer
mortality statistics, 2014. Available from: http://www.cancerresearchuk.org/health-professi-onal/cancer-statistics/worldwide-cancer/mortality #heading-Zero. Accessed 20 April 2015.
Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and activity of cancer research. Mol Oncol. 2008;2(1):20-32.
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicitiy and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
Voskoboynik M, Arkenau H. Challenges of Patient Selection for Phase I Oncology Trials. In: Vallisuta O, Olimat S, eds. Drug Discovery and Development. Croatia: InTech; 2015: 65-82.
